Haleon (NYSE:HLN) Posts Earnings Results, Misses Estimates By $0.13 EPS

Haleon (NYSE:HLN) announced its quarterly earnings results on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.13), FiscalAI reports. The firm had revenue of $3.71 billion during the quarter, compared to analyst estimates of $7.43 billion.

Haleon Stock Down 1.7%

HLN stock traded down $0.17 on Thursday, hitting $10.11. 16,090,150 shares of the company’s stock were exchanged, compared to its average volume of 9,834,686. The firm has a 50 day moving average price of $9.43 and a two-hundred day moving average price of $9.85. Haleon has a 12-month low of $8.65 and a 12-month high of $11.28. The stock has a market cap of $44.51 billion, a P/E ratio of 25.91, a price-to-earnings-growth ratio of 2.38 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Zacks Research cut shares of Haleon from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 21st. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Rothschild & Co Redburn cut shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Haleon has an average rating of “Moderate Buy”.

Institutional Investors Weigh In On Haleon

Several institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC acquired a new position in shares of Haleon during the fourth quarter valued at about $187,000. AQR Capital Management LLC boosted its stake in Haleon by 22.5% in the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after purchasing an additional 17,720 shares in the last quarter. Focus Partners Wealth grew its position in Haleon by 7.6% during the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after purchasing an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its position in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the last quarter. Finally, CW Advisors LLC increased its stake in Haleon by 11.6% during the 2nd quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.